Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells

Kadimastem

If the feasibility study is successful, it would be a significant step forward towards pancreatic tissue engineering that could be used to develop Kadimastem’s IsletRx for diabetes in a way where transplantation would be possible without concern of immune rejection Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring other neurodegenerative diseases and developing a potential cure for diabetes, has signed an agreement with Implant Therapeutics, Inc. for use of “Immune Evasive Cell” iACT cells, (Which are implant cells that the immune system does not recognize as foreign to the body) Implant's breakthrough technology to prevent transplant rejection. Under the terms of the agreement, a feasibility study will be conducted to test if Implant Therapeutic’s iACT TM cells can provide a solution to the challenge of transplant immune protection and avoidance of rejection of Kadimastem’s IsletRx for diabetes. If so, Implant Therapeutics iACT TM cells could be a good cell source for Kadimastem to create its glucose sensing, insulin producing pancreatic cells, the basis for IsletRx, without the need of Immune protection or immunosuppression. The iACT TM “Immune Evasive” cell technology uses genetic modifications to cloak cells to be seen as part of the receiving body’s immune system and therefore are not rejected following transplantation. The success of the licensing feasibility study would be a significant step forward towards the potential to create pancreatic islet organoids, capable of producing insulin and glucagon as well as regulating blood glucose levels, that would not be rejected by the body. A successful evaluation may result in the licensing by Kadimastem of Implant Therapeutics’ technology. Kadimastem CEO Asaf Shiloni said, “This strategic agreement with Implant is the result of a long-term effort we have invested in bringing the innovative “Immune Evasive” cell technology to Kadimastem. The new capability takes us to the forefront of the race to develop diabetes care and will allow us to apply advanced technologies to create an optimal and ultimate solution to the central problem of protecting cells from the patient's own immune system. I welcome the move and hope that this technology will further advance the development of IsletRx, with the ultimate goal of improving the lives of the millions of people living with diabetes worldwide." About IsletRx IsletRx is a cell therapy treatment for diabetes, achieved by expanding the population of allogeneic stem cells differentiated into functioning insulin and glucagon producing and releasing pancreatic islet cells. The company then uses a proprietary technology to select the highest functioning cells, enrich them and then transplant them into the body. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021, where the diabetes treatment program was discussed, and the company received directions how to prepare its Pre-IND submission. About Implant Therapeutics Implant Therapeutics is a subsidiary of panCELLa whose mission is to develop therapeutic products in the immunology and cell therapy space and to partner with other companies to develop novel products in areas of regenerative medicine. Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering human iPSC cells that incorporate failsafe, iACT, hypoimmunogenic and safe-harbor technologies. These iPSC cells are “Immune Evasive” and are an ideal choice for replacement strategies of many cell types combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. To learn more, visit www.implant-rx.com. About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

June 08, 2022 07:00 AM Eastern Daylight Time

Image

Telos Blockchain Sponsors Unbound Now Gala

Telos Foundation

The Telos Foundation is proud to announce that it will be the official sponsor for the 2022 Unbound Now Gala happening on June 7th in Waco, Texas. Telos is firmly in favor of all that Unbound Now stands for and has accomplished as a non-profit organization and is pleased to support them as they continue to provide aid for humanity’s most vulnerable. Tuesday’s gala celebrates 10 years of Unbound Now’s work to end human trafficking in local communities and around the world. Telos believes that global ESG concerns such as human trafficking, an illicit practice that has more than tripled in the last decade, must be eradicated at all costs. Unbound Now is leading the effort to help save the victims from this heartless act. Founded in the United States in 2012, Unbound Now has grown substantially, launching in several locations worldwide, including Cambodia, Mongolia, Indonesia, South Africa, and various countries in Europe. While their operations vary from one city to the next, Unbound offers three main lines of effort: Prevention and Awareness: Unbound Now works to educate and empower youth, spread awareness through citywide outreaches and provide human-trafficking presentations to groups and organizations. Professional Training: Unbound Now provides training to equip all professionals to use their skills to identify and serve victims of human trafficking. Survivor Advocacy: Unbound Now advocates for victims and survivors by meeting immediate needs, supporting survivors and their families, and connecting each survivor with resources for his or her unique restoration journey. The values and principles of the Telos team are closely aligned with those of Unbound Now and looks forward to making its contribution to put an end to human trafficking - once and for all. About Telos Live since 2018, Telos Blockchain (ticker: TLOS) is an ESG compliant Layer 1 smart contract platform that offers full-service compatibility with Solidity, Vyper and Native C++ smart contracts. The chain along with all of its departments operates at Net Zero status and offers the use of its fair smart contract powered governance system to any interested organization in modular fashion. The chain is capable of finalizing over a billion low-fixed-cost (w/ a feeless option) transactions per day. Since the launch of mainnet, Telos has operated with a flawless network uptime record. The validators of the network are globally decentralized, vetted (KYC) and are all equitable in size. Telos is one of the only Layer 1 Blockchain to be both credibly neutral in both its finances and its architecture. About The Foundation The Telos Foundation is a Decentralized Autonomous Organization established as a promotional and funding body to advance the Telos Blockchain Network and provide support to network applications. Contact Details The Team hello@telosfoundation.io Company Website https://www.telos.net/

June 07, 2022 10:21 AM Eastern Daylight Time

Video

Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference

Vascudyne, Inc.

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that the first clinical results of TRUE AVC™ acellular vascular conduit in hemodialysis access will be presented at the Vascular Access Society of the Americas (VASA) conference in Charleston, South Carolina at 11:20 am EDT on June 10, 2022. The presentation, titled “First in Human Evaluation of a Novel Biologic Regenerative Vascular Conduit for Hemodialysis Access”, will be made by Vascudyne’s medical advisor Monnie Wasse, MD, MPH, FASN, Professor of Medicine in the Division of Nephrology and Department of Internal Medicine at Rush University Medical Center. Dr. Wasse serves as Vice-Chairperson for Clinical Operations for the Department of Medicine and is also the Director of Interventional Nephrology, focused on the planning and maintenance of dialysis vascular access for patients with kidney diseases. Dr. Wasse will present 6-month results and preliminary evidence of the safety and effectiveness of the device as a conduit for hemodialysis vascular access. Vascudyne’s TRUE™ Tissue products are unique, 100% biological, and become the patient’s own living and functional tissue. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine cardiovascular devices with synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response. “Dr. Wasse brings extensive experience and clinical expertise to our medical advisory board, and we are excited she is presenting the promising initial results from the TRUE AVC studies,” said Mark Stenoien, Vascudyne’s Chief Regulatory and Clinical Science Officer. Vascudyne announced in February its relocation to a high capacity GMP manufacturing facility to support TRUE AVC manufacturing through commercialization. “We are excited to share our first clinical results with our TRUE Tissue technology in hemodialysis access and have been working on developing our platform technology to address additional cardiovascular diseases” said Dr. Zeeshan Syedain, Vascudyne’s Chief Scientific Officer. “Our move to the new facility dramatically increased our GMP manufacturing space and added a dedicated cleanroom that is poised to support our ongoing TRUE AVC clinical studies all the way to commercialization,” added Dr. Syedain. TRUE AVC is not available for commercial sale. Dr. Monnie Wasse, MD, MPH, FASN Vascudyne’s Clinical Collaborators at Sanatorio Italiano in Asuncion, Paraguay Vascudyne’s TRUE AVC TM for Hemodialysis Access About Vascudyne Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE™ Tissue technology to develop TRUE to Nature™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/. About TRUE Tissue Technology TRUE™ Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft. Forward Looking Statements This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne’s actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact Details Sandy Williams, Marketing Director swilliams@vascudyne.com

June 07, 2022 09:23 AM Eastern Daylight Time

Image

ThreatModeler Announces New Patent for IaC-Assist

ThreatModeler Software, Inc

ThreatModeler, a leader in securing cloud infrastructure from design to deployment, today announced the issuance of their newest patent, which makes the IaC-Assist a proprietary technology. The patent, US Patent No. 20220004645A1, has been issued and granted as of April 26, 2022. With IaC-Assist, any user can truly shift left as it relates to implementing security within the code. Users can identify, review, and mitigate security flaws while writing the code in real-time - with simply the click of a button and without leaving their coding environment. IaC-Assist creates a more time and cost-efficient solution to the build process, saving developers the hours it would have taken to build designs and review its security. “Our patented solution, IaC-Assist, reduces threat drift from code to cloud and gives users a simple and efficient solution in truly shifting left,” said Archie Agarwal, Founder and CEO, ThreatModeler. “This patented technology is the only solution in the industry that helps you build threat models from your IDE itself and updates the threat model as you update the code. We’re excited to have these streamlined capabilities patented and available to users.” This patented technology solution is the first of its kind that helps to reduce threats from code to cloud. Users can implement the technology as a processor-executed method of generating a threat model from a code file. The system can analyze the code file, identify properties associated with the resources included in the code file, and generate a threat model based on the resources determined as a security threat. This technology addresses industry pain points by giving tools for security teams to work more collaboratively with the development organizations. Additionally, instead of adding more steps to the build and deploy process, this technology fits within the existing process and enables developers to build security within the code with the least amount of time lost. To learn more about this new patent and ThreatModeler technology, please visit here. About ThreatModeler Software, Inc. ThreatModeler Software, Inc. 's suite of products empowers DevOps to measure their threat drift from code to cloud. With a fraction of the time and cost tied to other tools, users can design, build and validate threat drift from development to deployment. Teams can instantly visualize their attack surface, understand security requirements and prioritize steps to mitigate threats. CISOs can make critical security-driven business decisions to scale their infrastructure for growth. Contact Details Clayton Murtle ThreatModeler@luminapr.com

June 07, 2022 08:00 AM Eastern Daylight Time

Freight Rate Transparency gains traction in Freight Forwarding – SHIFEX by Shifl

Shifl

Digital forwarding and supply chain platform Shifl has announced the launch of SHIFEX, an Ocean Spot Freight Rate Index for container shipments which is now available on their website ( https://shifl.com/index ). The recent and continuing unprecedented chaos in the freight markets has brought the dire need for transparency and visibility into actual ocean freight rates. Shabsie Levy, CEO and Founder of Shifl, said he often found thousands of dollars of disparities between reported and actual freight rates on the market. “In the current market condition, just about no one can afford to pay hundreds and sometimes thousands of dollars more for moving a single container,” said Levy. SHIFEX provides live insights into ocean freight rates. It tracks and displays the average ocean spot freight rates for 40'containers (FEU) on main Transpacific routes at any given period. Freight rate transparency and accuracy have always been touted as core business values. They improve customer engagement, build trust, and increase productivity in an industry that has been opaque. “By leveraging our existing technology, we are helping shippers benchmark the freight rates they should be paying for their shipments and help them better plan their order placements and inventory” said Levy. By analyzing its own data of actual bookings and shipments, Shifl was able to alert the market in advance of the drastic changes in the ocean spot freight rates across the volatile periods in 2021 and 2022. Eli Gelbman of The New York Doll Collection a company that manufacturers and sells childrens dolls and accessories says, "I am pleased that Shifl is launching SHIFEX. As a regular importer, we have been following Shifl's rate data in their market reports which has helped us tremendously in managing the volatility in the freight market. Having the same info now on-demand, will allow us to make better supply chain decisions, and improve efficiency in costing and in planning our orders." More about SHIFEX SHIFEX, the first ocean spot freight rate index by a US freight forwarder, provides live insights into ocean spot freight rates as it tracks and displays rates that are applicable on the Trans-Pacific route. SHIFEX is based on the actual spot freight rates quoted and/or paid for moving shipments on the Trans-Pacific route and is therefore a true reflection of the prevailing market conditions in the freight forwarding spot market. SHIFEX is offered as a free service by Shifl and covers Port to Port container spot freight rates. SHIFEX includes all commonly applicable surcharges, —including but not limited to BAF (Bunker and/or Emergency Bunker Adjustment Factor), CAF (Currency Adjustment Factor) ISPS (International Security Port Surcharge), PCS (Port congestion surcharge). The index provides past and current freight rates with the option of tracking rates on a 3, 5, 12 and 18 month basis from the base ports of China to both Los Angeles and New York. In addition to freight rates, Shifl is also planning to include its highly popular vessel transit and container dwell data and add spot freight rates of other trade lanes to SHIFEX so customers can track the past and current performance of these metrics as well. SHIFEX complements digital offerings that include Shifl.com, the digital forwarding and supply chain platform, and Shifl.capital, the cutting-edge FinTech solution designed to make business transactions easier for supply chain companies. About Shifl Shifl is leading the supply chain industry into the future with technology and innovation that brings a huge array of real-life benefits to its users. If you are a shipper looking to bring your business into today's digital age, be more in control, and pay less overall - Shifl is for you. Shifl is headquartered in New York and maintains a presence in China, India, Vietnam, Malaysia, Bangladesh, Georgia, DR, and The Philippines. To learn more, visit https://shifl.com. Contact Details CHARLIE PESTI Priyanka Ann Saini +91 98332 68264 priyanka@pesti.io

June 06, 2022 12:00 AM Eastern Daylight Time

CMEs Available at Integrative Health & Medicine Conference in October 2022

Academy of Integrative Health and Medicine

The 2022 Academy of Integrative Health & Medicine (AIHM) annual “ People. Planet. Purpose. Conference ” has been accredited by the University of California, Irvine, School of Medicine for continuing medical education (CME) credits. The conference, themed “Disruptive Innovation + the Future of Health,” will be held Oct. 28-30 in San Diego. Participation is available for in-person and virtual attendance options. Attendees can earn up to 54.25 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME credit breakdown as follows: Thursday, Oct. 27, pre-conference seminar, “Update on Hormone Therapy in Integrative Practice” – 3.75 Thursday, Oct. 27, pre-conference seminar, “Introduction to Psychedelic Assisted Psychotherapy: Clinical Use + Emerging Research” – 3.75 Friday, Oct. 28, general session – 6.5 Saturday, Oct. 29, general session – 5.75 Sunday, Oct. 30, general session – 4.5 On-demand virtual presentations – 30 People. Planet. Purpose. features experts, innovators, and visionaries in integrative health and medicine from across the globe talking about the latest research-based integrative techniques and strategies. Presenters include Deepak Chopra, MD; Sara Gottfried, MD; Shamini Jain, PhD; Scott Shannon, MD, ABIHM; Mimi Guarneri, MD; and Romie Mushtaq, MD, among others. More information and registration is available at aihm.org/conference. Early-bird pricing ends August 15. “Each year our presenters share ground-breaking developments and advances in truly integrative approaches to health, wellness and medicine,” said AIHM Executive Director Tabatha Parker, ND. “The AIHM conference allows physicians and other clinicians from a wide range of specialties to expand their understanding of whole-person care.” CME Information This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and the Academy of Integrative Health & Medicine. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, www.meded.uci.edu/cme, for AB 1195 and AB 241 resources. Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. Contact Details Carol Stevenson +1 661-713-6879 carol@growthledge.com Company Website https://aihm.org

June 03, 2022 04:36 PM Eastern Daylight Time

CORRECTING and REPLACING AmeriLife & The American Home Life Insurance Company Team Up to Launch Medicare Supplement & Final Expense Combo Solution

AmeriLife

The headline of the release dated June 1st, 2022 has been updated to read "AmeriLife & The American Home Life Insurance Company Team Up to Launch Medicare Supplement & Final Expense Combo Solution" sted "AmeriLife & The American Home Life Insurance Company Team Up to Launch Medicare Supplement & Financial Expense Combo Solution" The updated release reads: AmeriLife & The American Home Life Insurance Company Team Up to Launch Medicare Supplement & Final Expense Combo Solution Featuring AHL’s industry-leading Medicare Supplement and Patriot Series final expense products, unique combination delivers a one-two punch for today’s agents and customers AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, today announced the launch of a ground-breaking, Medicare Supplement/final expense combination solution developed in partnership with The American Home Life Insurance Company (AHL) and designed to deliver two great products together to better address customers’ holistic needs. “We are extremely excited to partner with AmeriLife to offer highly competitive Medicare Supplement and Final Expense products intentionally designed to facilitate combination sales,” said Tom Lobell, executive vice president and chief marketing officer of AHL. “Between our one-of-a-kind e-app technology, which enables both applications to be completed simultaneously from a single enrollment, and the extensive cost savings clients can access by bundling products, combination sales will never be easier.” For customers, AHL’s Medicare Supplement and Patriot Series final expense products work in tandem to deliver the freedom provided by traditional Medicare along with the peace of mind in knowing their loved ones will not have to bear the burden of their funeral costs. In addition to highly competitive rates, The Patriot Series features a simple, electronic application process, instant underwriting, and seamless premium payments via direct billing through Social Security. For agents, the combination is game-changing. Once clients have qualified for the Medicare Supplement plan, they’re a few questions away – with no phone call required – from being accepted for their discounted, super-preferred Patriot Series final expense policy. And with a discount of up to 20% when combined with the Medicare Supplement plan, agents will help save their clients money year after year and improve client retention. “This new solution is the rewarding combination agents and clients have been waiting for,” said David Paul, national sales director for Simplified Issue Life at AmeriLife. “With a front-loaded commission structure alongside generous bonuses, agents don’t have to let their marketing costs be a roadblock to success – especially while agents learn a new product to better cover their clients’ holistic needs.” “It’s rare that you see a solution with more benefits and less complexity, but this unique combination achieves exactly that,” added Greg Etchison, vice president of Medicare Supplement and Specialty Health for AmeriLife. “It’s a solution made with customers in mind – the way insurance was intended to be – and we’re excited with its potential to help grow our agents’ businesses.” The launch of this combo solution continues AmeriLife’s intense focus on delivering innovative product design, and its partnership with AHL remains a testament to the companies’ shared values and approach to developing modern health and financial planning solutions. “Final expense is continuing to have its moment — and for good reason — as individuals reassess their needs, and those of their loved ones, for their final days,” said Pat Fleming, executive vice president, Product Innovation & Corporate Actuary at AmeriLife. “By combining final expense and Medicare Supplement products under one, simple solution, AmeriLife and AHL are bringing to market a holistic solution that is in line with our unique approach to addressing clients’ total health and financial wellbeing.” To learn more about this new combo solution from AmeriLife and AHL, including details on coverage amounts and other benefits, visit ahlpatriotseries.com. ### About AmeriLife AmeriLife’s strength is its mission: to offer insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 insurance agents and advisors, more than 50 marketing organizations, and 50 insurance agency locations. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About The American Home Life Insurance Company The American Home Life Insurance Company (AHL) was founded in 1909 in Topeka, Kansas, under the name Kansas Home Mutual Life Insurance Company. In 1912, the Company merged with the American Mutual Life Insurance Company of McPherson, Kansas, and adopted its current name, The American Home Life Insurance Company, which the company has operated under for over 100 years. Throughout the last century, AHL’s mutual corporate structure, conservative investment philosophy, and Midwestern value-oriented culture have enabled it to grow and prosper through multiple world wars, epidemics and recessions while fulfilling its commitments to its policyholders, agents and employees. To learn more, visit amhlifeco.com. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com The American Home Life Insurance Company Tom Lobell +1 800-876-0199 tlobell@amhomelife.com Company Website https://amerilife.com/

June 02, 2022 09:22 PM Eastern Daylight Time

Clear Cannabis Inc. Launches Legacy Brand The Clear™ In Montana Through Bloom MT Partnership

Clear Cannabis Inc.

Clear Cannabis Inc. (CCI), national licensor of legacy cannabis brand The Clear™ announces an exclusive partnership with licensed Cannabis provider Bloom Montana. “We are ecstatic to establish this partnership and be one of the first nationwide cannabis brands in the great state of Montana, ” said Seth Wiggins, President of CCI. “With a newly legalized adult-use market, we know there’s a growing demand for high quality, consistent cannabis products from a reputable brand. As pillars of brand value, The Clear will certainly deliver for the cannabis consumer in Montana.” The Clear was one of the original cannabis brands and was the first to bring molecular distillation to the legal cannabis market in 2013. Since then, they have won multiple cannabis industry awards for their products and all-natural flavors, including awards in the High Times Cannabis Cup in Michigan, Las Vegas Cannabis Awards, and THC Classics in Colorado. The Clear products will be available to purchase in Montana dispensaries starting in July 2022 and includes The Clear Elite distillate 1000mg and 500mg cartridges. They will also offer their Elite All-In-One 350mg disposable vape pen in their award-winning botanically derived flavors. The flavors include Blue Raz, Golden Goat, Grapevine, Lime Sorbet, Orange Cream, and OG. “As a reliable, well-established brand providing high-quality, consistent products, The Clear is an ideal brand for Big Sky Country,” said John Hoofman Jr., Principal Owner of Bloom MT. Consumers who are waiting to try The Clear products in Montana can find them starting in July primarily in the following regions – Billings, Bozeman, Missoula, Helena, Butte, Kalispell, Sidney, and Havre. The initial product launches will be at Bloom, Sweetgrass, and Fat Hippie dispensaries. Products will be made available to all Montana licensed distribution partners in the upcoming months. Contact The Clear directly to inquire at info@clearconcentrate.com. Following the launch of its flagship Elite Line this summer, The Clear is planning to bring both their ENDO live resin cartridges and TWAX Infused Pre-rolls to Montana in the latter half of 2022. About Clear Cannabis, Inc. The Clear™ is one of the original cannabis brands. The brand was founded in 2013 by a team of scientists who introduced molecular distillation to the legal cannabis market and in the process reinvented the cannabis industry. As a national cannabis brand and licensor of The Clear™, Clear Cannabis, Inc. products are available in multiple cannabis markets in the U.S. The company is focused on product consistency regardless of state, proprietary formulations, product safety, consumer experience, and expanding product lines. Contact Details Clear Cannabis Inc. Rebecca Maestas Sincere, Executive Director of Marketing +1 720-330-5000 r.sincere@clrcan.com

June 02, 2022 09:00 AM Mountain Daylight Time

Image

AllerVie Health Presents AllerVie Clinical Research & Expands Clinical Research Division Nationwide

AllerVie Health

Today, AllerVie Health announced the milestone accomplishment and unveiling of the new brand for their affiliate, AllerVie Clinical Research. Formerly known as Clinical Research Center of Alabama, AllerVie Clinical Research brings cutting-edge treatments and medical advancements to patients who need them most by contributing to the development of innovative, new therapies that connect patients and physicians to the future of medicine. Championing innovative clinical research built to scale for pharmaceutical sponsorship partners, Contract Research Organizations, and patients across the United States, AllerVie Clinical Research offers more clinical research studies in asthma, allergy, and related immunological conditions than any other organization in the nation through our network of national clinical research sites. In collaborative partnership with sponsors and AllerVie board-certified allergists, AllerVie Clinical Research is pioneering new therapies based on years of experience in clinical research and the field of allergy and immunology. This rebranding positions AllerVie Clinical Research for increased nationwide expansion, mirroring the dynamic growth of AllerVie Health’s allergy clinic footprint over the last 15 months. Together, the two organizations are poised for continued growth with eyes on the future. “We firmly believe that best practice is derived from the best clinical research,” said Chief Research Officer, Dr. John Anderson. “As we expand our clinical research footprint in tandem with our allergy clinic footprint, we have complete confidence in our ability to pursue life-changing clinical trials in diverse populations across the country. We believe that hope is having options, and the work that we are doing has life-transforming impact on patients today and into the future.” National Director of Research, Christopher Ingraham, Ph.D., agrees, “We are unique and transformative in this space in our approach to combining best clinical practice across the country with a network of clinical research sites. We are taking care of the administrative aspects of clinical research so that our allergists and immunologists can still see patients, operate productive and thriving practices, and contribute to the future of medicine through clinical research. In this model, everyone wins.” Learn more about how AllerVie Clinical Research is changing lives every day for participating patients, our clinical research studies, and our past sponsorship partners by visiting www.allervieclinicalresearch.com. About AllerVie Health AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, currently serving patients across 12 states in over 75 clinic locations. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, reclaim their lives, and live in freedom! To learn more about our practices, our approach, and our vision, visit www.allervie.com. About AllerVie Clinical Research AllerVie Clinical Research, an affiliate of AllerVie Health, conducts clinical studies in adult and pediatric patients, contributing to the advancement of new therapies for asthma, allergies, and other related immunological conditions. We provide access to otherwise unavailable treatments to patients suffering from these conditions. As the fastest growing national network of clinical research sites specializing in allergy and asthma-related studies, AllerVie Clinical Research provides comprehensive care to patients nationwide employing the most efficacious and up-to-date treatments—including biologics. Highly regarded for their standards of excellence, our providers have been conducting clinical trials for pharmaceutical companies and Contract Research Organizations since 1998, giving us more than 20 years of successful clinical research experience in this area of immunological diseases. To learn more, visit www.allervieclinicalresearch.com. Contact Details AllerVie Health/AllerVie Clinical Research Rachel Russell, Chief Marketing Officer rrussell@allervie.com

June 01, 2022 04:00 PM Central Daylight Time

1 ... 215 216 217 218 219 ... 301